Annals of Surgical Oncology

, Volume 24, Issue 3, pp 745–753

Increasing the Number of Examined Lymph Nodes is a Prerequisite for Improvement in the Accurate Evaluation of Overall Survival of Node-Negative Gastric Cancer Patients

Gastrointestinal Oncology

DOI: 10.1245/s10434-016-5513-8

Cite this article as:
Deng, J., Yamashita, H., Seto, Y. et al. Ann Surg Oncol (2017) 24: 745. doi:10.1245/s10434-016-5513-8

Abstract

Background

This study aims to elucidate whether increasing the number of examined lymph nodes (NELN) is mandatory for the accurate prognosis of node-negative gastric cancer (GC) patients after curative gastrectomy in Eastern countries (China and Japan).

Methods

The clinicopathological data of 2455 GC patients (including 1137 node-negative cases) were included to demonstrate whether a minimum NELN is inevitable for guaranteeing the accurate prognosis of node-negative GC patients after curative gastrectomy.

Results

Survival analyses revealed that the NELN significantly positively correlated with overall survival (p < 0.001) and was an independent prognostic predictor (hazard ratio 0.447; p = 0.025) of 1137 node-negative GC patients. Stratum analysis within the Kaplan–Meier method showed that sex, tumor size, and extent of lymphadenectomy did not affect the NELN in predicting the prognosis of all node-negative GC patients. Stage migration was mainly detected in the subgroup of node-negative GC Chinese patients who presented considerably lower mean NELN and more advanced staging than patients from Japan. The NELN was identified as the most intensively independent predictor of prognosis of 600 node-negative GC patients from China, with the smallest Akaike information criterion (176.964) and Bayesian information criterion values (194.552). These findings indicate that increasing the NELN is a prerequisite to guaranteeing precise TNM classification.

Conclusions

The NELN should be considered a mandatory requirement for improving the accuracy of prognostic evaluation of GC patients, especially for advanced-stage patients.

Supplementary material

10434_2016_5513_MOESM1_ESM.doc (271 kb)
Supplementary material 1 (DOC 270 kb)
10434_2016_5513_MOESM2_ESM.tif (106 kb)
Survival curve of 2245 GC patients according to N stage subgroups. (TIF 106 kb)
10434_2016_5513_MOESM3_ESM.tif (62 kb)
Survival curve of 537 GC patients in the University of Tokyo Hospital. (TIF 62 kb)
10434_2016_5513_MOESM4_ESM.tif (68 kb)
Survival curve of 600 GC patients in the Tianjin Medical University CancerHospital. (TIF 67 kb)
10434_2016_5513_MOESM5_ESM.tif (89 kb)
Stage migration comparison of patients according to pT1 tumor. (TIF 89 kb)
10434_2016_5513_MOESM6_ESM.tif (86 kb)
Stage migration comparison of patients according to pT2 tumor. (TIF 85 kb)
10434_2016_5513_MOESM7_ESM.tif (85 kb)
Stage migration comparison of patients according to pT3 tumor. (TIF 85 kb)
10434_2016_5513_MOESM8_ESM.tif (87 kb)
Stage migration comparison of patients according to pT4 tumor. (TIF 87 kb)

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  1. 1.Department of Gastroenterology, Tianjin Medical University Cancer HospitalCity Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for CancerTianjinChina
  2. 2.Department of Stomach and Esophageal SurgeryThe University of Tokyo HospitalTokyoJapan

Personalised recommendations